Transitional cell carcinoma
RecruitingStudy of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment
Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment
- Disease:Transitional cell carcinoma
- Substances:CarboplatinCisplatin+2
Italy- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:Daiichi Sankyo Inc.











